CIP
AVDL

Chartwell Investment Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Chartwell Investment Partners’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-55,065
Closed -$437K – 406
2020
Q1 		$437K Buy
+55,065
New +$423K 0.02% 370
2016
Q1 		– Sell
-229,268
Closed -$2.8M – 323
2015
Q4 		$2.8M Sell
229,268
-5,280
-2% -$82.3K 0.06% 254
2015
Q3 		$3.83M Buy
234,548
+4,423
+2% +$97.4K 0.08% 236
2015
Q2 		$4.88M Buy
+230,125
New +$4.13M 0.1% 225
2015
Q1 		– Sell
-120,707
Closed -$2.07M – 329
2014
Q4 		$2.07M Buy
+120,707
New +$1.72M 0.04% 310

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Chartwell Investment Partners's AVDL Position: Q2 2020 in Review

Chartwell Investment Partners sold out of Avadel Pharmaceuticals (AVDL) in Q2 2020, closing a stake of 55,065 shares — an estimated $437K sold.

Chartwell Investment Partners first reported a position in AVDL in Q4 2014 and held it in 5 quarters. The position peaked at $4.88M in Q2 2015. 74 funds tracked by Wall St. Rank hold AVDL as of Q2 2020.

  • Chartwell Investment Partners reported no remaining Avadel Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Chartwell Investment Partners sold 55,065 Avadel Pharmaceuticals shares in Q2 2020, an estimated $437K.
  • Chartwell Investment Partners first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 5 quarters.
  • Chartwell Investment Partners's Avadel Pharmaceuticals position peaked at $4.88M in Q2 2015.
  • 74 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2020.

Based on Chartwell Investment Partners's 13F filing for Q2 2020, filed 29 Jul 2020.